News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Bitget UEX Daily | US-Iran Talks Remain Divided but Ceasefire Expectations Boost US Stocks; Google Releases Cache Compression Technology Impacting Storage Sector (March 26, 2026)2PDD Holdings 2025 Q4 Earnings: Growth Significantly Slows, Full Bet on Supply Chain Investment to Build the "New Pinduoduo"3Hard to go long, hard to go short! Nomura strategist: "Current macro volatility, trading poses career risks"; Goldman Sachs analyst: "Cash is king"
Blockchain philanthropy fails Africa’s real-world test
Cointelegraph·2026/03/26 12:33
Lanvin Group Surges 12% on No News
101 finance·2026/03/26 12:24
AAVE Drops 5.5% as Marriott Beats Expectations
101 finance·2026/03/26 12:24
Chainlink/Union Breaks $9.20 as Sellers Take Control
101 finance·2026/03/26 12:21
Bernstein Analysts Say Strategy Stock (MSTR) Could Explode 220% If Bitcoin Has Bottomed
Tipranks·2026/03/26 12:18
EUR/GBP: Potential for gains as BoE shifts towards a more dovish stance - ING
101 finance·2026/03/26 12:15
Cielo Waste Solutions Faces Binary Call as April 15 Deadline Looms Over Dilutive Deal Risks
101 finance·2026/03/26 12:13
Battalion Oil Jumps 10% Without News as S&P Slides
101 finance·2026/03/26 12:06
Is Bitcoin’s governance too slow to fend off quantum risks?
Cointelegraph·2026/03/26 12:00
XRP (Ripple) holders have just been given remarkable updates from the Securities and Exchange Commission
101 finance·2026/03/26 11:57
Flash
12:30
In the week ending March 21, initial jobless claims in the United States were 210,000, in line with expectations.BlockBeats News: In the week ending March 21, initial jobless claims in the United States were 210,000, in line with expectations, with a previous value of 205,000. (Forex Factory)
12:28
VolitionRX Limited announced that its research abstract on lung cancer risk stratification has been officially released at the European Lung Cancer Congress.This research demonstrates the potential of using novel biomarkers for lung cancer risk stratification, providing important evidence for early diagnosis and personalized treatment. The publication of these results marks another significant advancement for the company in the field of tumor diagnosis.
12:28
According to a public SEC filing, biopharmaceutical company Dianthus Therapeutics Inc. (DNTH) is adjusting the enrollment criteria for the clinical trial of its core drug Claseprubart.The company plans to formally submit these amendment proposals to the U.S. Food and Drug Administration for review in the first quarter of 2026.
News